A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Trial Profile

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs NGM 282 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors NGM Biopharmaceuticals
  • Most Recent Events

    • 22 Apr 2017 Results (n=82) published in a NGM Biopharmaceuticals media release.
    • 22 Apr 2017 Primary endpoint (Change in absolute liver fat content as measured by MRI from Baseline to Week 12) has been met, according to a NGM Biopharmaceuticals media release.
    • 08 Mar 2017 Treatment arm changed from 3 to 5 with addition of an open label single-blind cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top